Bayer Files Larotrectinib In EU As LOXO-292 Hurtles Towards The Market
An EU filing by licensee Bayer puts Loxo Oncology’s larotrectinib on track to be the first tropomysosin receptor kinase inhibitor to reach the market there. Meanwhile, Loxo’s second product, LOXO-292, is speeding its way to a US filing.
You may also be interested in...
Patients in France are to receive Bayer’s Vitravki through an early access scheme pending the product's EU-wide marketing authorization.
Vitrakvi is effective against a wide variety of cancers driven by NTRK fusion. But finding the patients who will benefit will be a challenge, given there are expected to be only around 2,500 to 3,000 new cases in the US and testing for the mutation is uncommon.
Keeping Track: Pfizer’s Talzenna Ensures Record Year For Novel US Approvals; Novartis Submits SMA Gene Therapy
The latest drug development news and highlights from our FDA Performance Tracker.